Zacks Research Reduces Earnings Estimates for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Henry Schein in a research note issued to investors on Tuesday, March 18th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.11 for the quarter, down from their prior forecast of $1.17. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.21 EPS, Q3 2025 earnings at $1.26 EPS, Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.84 EPS, Q1 2026 earnings at $1.32 EPS, Q2 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.39 EPS, FY2026 earnings at $5.31 EPS and FY2027 earnings at $5.74 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.66 earnings per share.

Other equities research analysts also recently issued research reports about the company. UBS Group dropped their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group increased their price objective on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Barrington Research reaffirmed an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a report on Wednesday, February 26th. Wells Fargo & Company initiated coverage on shares of Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Finally, Mizuho initiated coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.10.

Henry Schein Stock Performance

Shares of HSIC stock opened at $69.39 on Thursday. The firm’s 50 day moving average is $74.82 and its 200 day moving average is $72.60. The stock has a market capitalization of $8.62 billion, a P/E ratio of 28.56, a PEG ratio of 2.13 and a beta of 0.90. Henry Schein has a 12 month low of $63.67 and a 12 month high of $82.49. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. grew its holdings in Henry Schein by 0.4% during the fourth quarter. Invesco Ltd. now owns 4,963,409 shares of the company’s stock valued at $343,468,000 after purchasing an additional 17,552 shares during the period. FMR LLC lifted its position in shares of Henry Schein by 6.6% during the 4th quarter. FMR LLC now owns 3,498,033 shares of the company’s stock valued at $242,064,000 after buying an additional 217,143 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Henry Schein by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company’s stock valued at $218,762,000 after acquiring an additional 14,876 shares during the period. Palestra Capital Management LLC purchased a new stake in Henry Schein in the 4th quarter worth approximately $182,988,000. Finally, Southpoint Capital Advisors LP raised its stake in Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after acquiring an additional 600,000 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Bradford C. Connett sold 4,036 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.